Placement to Raise $3.25 million

• Successful $3.25M private placement of 50M new shares
• Placement anchored by long-time investor Reitham Equity
• Funds to accelerate commercialization of assistive tech products

Control Bionics Limited (ASX: CBL) has successfully completed a $3.25 million private placement of 50 million new fully paid ordinary shares at an issue price of $0.065 per share. The placement was anchored by Reitham Equity GmbH, a European private equity investor and long-standing supporter of Control Bionics. The funds raised will provide additional working capital to accelerate the company's commercialization programs across its core assistive technology products and emerging neurotechnology markets. Control Bionics CEO and Managing Director, Jeremy Steele, stated that the investment strengthens the company's balance sheet and enables it to progress key commercial initiatives across assistive communication, rehabilitation, and sports performance. The new shares issued under the placement will rank equally with existing fully paid ordinary shares and are expected to be issued on 5 December 2025.

The funds raised will provide additional working capital to accelerate the company's commercialization programs across its core assistive technology products and emerging neurotechnology markets.